Avecho Biotechnology Ltd has released a press release.
Response to ASX Price Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- December 2024 Quarterly Activities Report & Appendix 4C
- September 2024 Quarterly Activities Report & Appendix 4C
- June 2024 Quarterly Activities Report & Appendix 4C
- Chair's Address and CEO Presentation
- First Patient dosed in Phase III insomnia trial
Later from Avecho Biotechnology
- Appendix 4E - Preliminary Final Report
- Trading Halt
- Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS
- Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
- Avecho receives initial US$3M upfront payment from Sandoz
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology